News and Insights

CEO Adam Shames recently presented to a class at  McGill University . Students studying Translational Biomedical Engineering learned about  human factors in medical devices  as an illustration of regulatory affairs and quality management.

We partnered with kaleo, Inc. in the conduct of a  simulated-use human factors validation study  of a 0.1-mg epinephrine auto-injector that was developed to potentially help minimize the risk of striking bone during epinephrine injection in patients who weigh 7.5–15 kg (e.g., infants and young children). The findings of the study were presented as a  poster  at the 2018  American Academy of Allergy Asthma & Immunology Annual Meeting  in Orlando Florida. The  full text  of the article is now available online in the  Allergy and Asthma Proceedings .